Day One Biopharmaceutical Stock (NASDAQ:DAWN), Analyst Ratings, Price Targets, Predictions

The latest price target for Day One Biopharmaceutical (NASDAQ: DAWN) was reported by Needham on April 25, 2024. The analyst firm set a price target for $33.00 expecting DAWN to rise to within 12 months (a possible 88.57% upside). 20 analyst firms have reported ratings in the last year.

The latest analyst rating for Day One Biopharmaceutical (NASDAQ: DAWN) was provided by Needham, and Day One Biopharmaceutical reiterated their buy rating.

There is no last upgrade for Day One Biopharmaceutical.

The last downgrade for Day One Biopharmaceuticals Inc happened on April 25, 2023 when B of A Securities changed their price target from $34 to $9 for Day One Biopharmaceuticals Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Day One Biopharmaceutical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Day One Biopharmaceutical was filed on April 25, 2024 so you should expect the next rating to be made available sometime around April 25, 2025.

While ratings are subjective and will change, the latest Day One Biopharmaceutical (DAWN) rating was a reiterated with a price target of $0.00 to $33.00. The current price Day One Biopharmaceutical (DAWN) is trading at is $17.50, which is within the analyst’s predicted range.